PharmaShots

AlzeCure Partners with QuantumCell for NeuroRestore ACD856 in a Deal Worth up to $2.2B

Jul 3, 2026, 6:30 AM

Translate article text

Choose a language and wait for the translated text.

Shots: AlzeCure Pharma has entered into an out-licensing & collaboration agreement with QuantumCell for global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, incl. ACD856 AlzeCure will receive $12M upfront, incl. a $5M investment, & is eligible for development & commercial milestones exceeding $2.2B (excl. royalties), plus tiered single to low double-digit royalties NeuroRestore ACD856 is a small-molecule Trk-PAM that enhances NGF/TrkA and BDNF/TrkB signaling to improve cognition & has demonstrated neuroprotective, anti-inflammatory, and disease-modifying effects in preclinical studies Ref: AlzeCure | Image: AlzeCure & QuantumCell | Press Release Related News: Insilico Medicine Collaborates with Takeda to Advance AI Drug Discovery PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post AlzeCure Partners with QuantumCell for NeuroRestore ACD856 in a Deal Worth up to $2.2B appeared first on PharmaShots.